spironolactone has been researched along with Mitral Incompetence in 10 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
| Excerpt | Relevance | Reference |
|---|---|---|
| "For study purposes, advanced heart failure was defined as recurrence of congestive heart failure signs despite receiving the initially prescribed dose of pimobendan, angiotensin-converting-enzyme inhibitor (ACEI), and furosemide >4 mg/kg/day." | 3.88 | Clinical findings and survival time in dogs with advanced heart failure. ( Beaumier, A; Freeman, LM; Rush, JE; Yang, VK, 2018) |
| "To determine if the administration of an angiotensin-converting enzyme inhibitor (ACEI) plus spironolactone caused hyperkalemia, hypermagnesemia, or hyponatremia in elderly small dogs with degenerative mitral valve disease (MVD)." | 3.74 | Influence of combined angiotensin-converting enzyme inhibitors and spironolactone on serum K+, Mg 2+, and Na+ concentrations in small dogs with degenerative mitral valve disease. ( Calvert, CA; Fallaw, TK; Rockwell, JE; Thomason, JD, 2007) |
| "Spironolactone treatment demonstrated significant attenuation of cardiac fibrosis and apoptosis in left ventricular tissue compared to furosemide." | 1.72 | Mineralocorticoid Receptor Antagonists Mitigate Mitral Regurgitation-Induced Myocardial Dysfunction. ( Chang, WT; Chen, CY; Chen, ZC; Lin, YW; Liu, PY; Luo, CY; Shih, JY; Wu, CC, 2022) |
| "cardiac death or death for other causes)." | 1.62 | Multiple retrospective analysis of survival and evaluation of cardiac death predictors in a population of dogs affected by degenerative mitral valve disease in ACVIM class C treated with different therapeutic protocols. ( Bagardi, M; Brambilla, PG; Galizzi, A; Locatelli, C; Malchiodi, D; Zanaboni, A, 2021) |
| "Their mitral regurgitation (MR) is a result of left ventricular (LV) geometrical distortion." | 1.33 | Flexible versus nonflexible mitral valve rings for congestive heart failure: differential durability of repair. ( Bolling, SF; Geltz, A; Spoor, MT, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (30.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 1 (10.00) | 24.3611 |
| 2020's | 3 (30.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, WT | 1 |
| Lin, YW | 1 |
| Chen, CY | 1 |
| Chen, ZC | 1 |
| Shih, JY | 1 |
| Wu, CC | 1 |
| Luo, CY | 1 |
| Liu, PY | 1 |
| Tanaka, S | 1 |
| Imamura, T | 1 |
| Ueno, H | 1 |
| Kinugawa, K | 1 |
| Bagardi, M | 1 |
| Locatelli, C | 1 |
| Zanaboni, A | 1 |
| Galizzi, A | 1 |
| Malchiodi, D | 1 |
| Brambilla, PG | 1 |
| Beaumier, A | 1 |
| Rush, JE | 1 |
| Yang, VK | 1 |
| Freeman, LM | 1 |
| KUKES, VG | 1 |
| Martin, N | 1 |
| Ott, R | 1 |
| Klues, HG | 1 |
| Spoor, MT | 1 |
| Geltz, A | 1 |
| Bolling, SF | 1 |
| Thomason, JD | 1 |
| Rockwell, JE | 1 |
| Fallaw, TK | 1 |
| Calvert, CA | 1 |
| Olesen, KH | 1 |
| Valentin, N | 1 |
10 other studies available for spironolactone and Mitral Incompetence
| Article | Year |
|---|---|
Mineralocorticoid Receptor Antagonists Mitigate Mitral Regurgitation-Induced Myocardial Dysfunction.
Topics: Animals; Fibrosis; Furosemide; Heart Failure; Mineralocorticoid Receptor Antagonists; Mitral Valve I | 2022 |
MitraClip or Ventricular Assist Device?
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiac Resynchronization The | 2020 |
Multiple retrospective analysis of survival and evaluation of cardiac death predictors in a population of dogs affected by degenerative mitral valve disease in ACVIM class C treated with different therapeutic protocols.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Cohort Studies; Death; Dog Diseases; Dogs; Female | 2021 |
Clinical findings and survival time in dogs with advanced heart failure.
Topics: Animals; Cardiotonic Agents; Dog Diseases; Dogs; Female; Furosemide; Heart Failure; Male; Mitral Val | 2018 |
[ON USE OF THE BLOCKING AGENT ALDOSTERONE].
Topics: Aldosterone; Aortic Valve; Diuretics; Heart Failure; Humans; Hyperaldosteronism; Mitral Valve Insuff | 1963 |
[Idiopathic hypereosinophilia with cardiac involvement].
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cardiomyopathy, Restrictiv | 2004 |
Flexible versus nonflexible mitral valve rings for congestive heart failure: differential durability of repair.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiomyopathy, Dilated; Combined Modality | 2006 |
Influence of combined angiotensin-converting enzyme inhibitors and spironolactone on serum K+, Mg 2+, and Na+ concentrations in small dogs with degenerative mitral valve disease.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Diuretics; Dog Diseases; Dogs; Drug Interactions; | 2007 |
Total exchangeable potassium, sodium and chloride in patients with severe valvular heart disease during preparation for cardiac surgery.
Topics: Adult; Aortic Valve Insufficiency; Atrial Fibrillation; Bicarbonates; Blood Proteins; Body Compositi | 1973 |
Heart failure. II.
Topics: Aged; Aortic Valve Insufficiency; Digitoxin; Digoxin; Ethacrynic Acid; Female; Furosemide; Heart Fai | 1971 |